EGX
8.62 EGP
+7.75%From 6 to 12 months
Buy stock at the current price
September 15, 2025 at 8:38:37 AM
Medium
85.00%
7.75%
Ibnsina Pharma has demonstrated robust financial performance, with a significant revenue increase of 64.49% in 2024, reaching EGP 55.84 billion. The company's net income also surged by 187.51% to EGP 614.56 million, indicating strong operational efficiency. Additionally, analysts have assigned a 'Strong Buy' rating, with a 12-month price target of EGP 8.62, suggesting confidence in the stock's future performance.
Over the past year, Ibnsina Pharma's stock has appreciated by approximately 166.67%, reflecting strong market confidence. The stock reached its 52-week high of EGP 8.13 on March 13, 2025.
The Egyptian pharmaceutical sector is experiencing growth due to increasing healthcare demands and government initiatives to improve healthcare infrastructure. This favorable environment supports Ibnsina Pharma's expansion and revenue growth.
As a leading pharmaceutical distributor in Egypt, Ibnsina Pharma serves a diverse clientele, including retail chains, independent pharmacies, wholesalers, hospitals, and healthcare institutions. The company's extensive distribution network and value-added services, such as warehousing, logistics, and market research, provide a competitive edge in the market.
Ibnsina Pharma exhibits strong financial growth, a dominant market position, and operates within a growing industry. With a current price of EGP 8.00 and a target price of EGP 8.62, the stock presents a promising investment opportunity.
- Strong financial growth with 64.49% revenue increase in 2024.
- Analysts rate the stock as 'Strong Buy' with a target price of EGP 8.62.
- Dominant market position serving diverse clientele.
- Operating in a growing industry with favorable economic factors.
